Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth H Mayer

Showing results (971-980 of 997) with videos related to

Pageof 100
Sort By:
Microbiology Spectrum|March 23, 2026
Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathwaysSean M Hughes, Fernanda L Calienes, Claire N Levy, et al.
The Journal of the Association of Nurses in AIDS Care : JANAC|January 18, 2023
Validity Properties of a Self-reported Modified Frailty Phenotype Among People With HIV in Clinical Care in the United StatesStephanie A Ruderman, Allison R Webel, Amanda L Willig, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The Journal of Infectious Diseases|November 5, 2016
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
The Journal of Infectious Diseases|October 13, 2011
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trialSusan H Eshleman, Sarah E Hudelson, Andrew D Redd, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2021
Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020Adrienne E Shapiro, Rachel A Bender Ignacio, Bridget M Whitney, et al.
Annals of Internal Medicine|August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized TrialRoy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Plos Genetics|April 26, 2014
Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemicLaura A Cotton, Xiaomei T Kuang, Anh Q Le, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 1, 2022
Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March-December 2020Adrienne E Shapiro, Rachel A Bender Ignacio, Bridget M Whitney, et al.
AIDS and Behavior|October 28, 2024
Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time among People with HIV in the Current Treatment EraJimmy Ma, Joseph A C Delaney, Stephanie A Ruderman, et al.
Pageof 100

Showing results (971-980 of 997) with videos related to

Sort By:
Pageof 100
Microbiology Spectrum|March 23, 2026
Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathwaysSean M Hughes, Fernanda L Calienes, Claire N Levy, et al.
The Journal of the Association of Nurses in AIDS Care : JANAC|January 18, 2023
Validity Properties of a Self-reported Modified Frailty Phenotype Among People With HIV in Clinical Care in the United StatesStephanie A Ruderman, Allison R Webel, Amanda L Willig, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
The Journal of Infectious Diseases|November 5, 2016
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
The Journal of Infectious Diseases|October 13, 2011
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trialSusan H Eshleman, Sarah E Hudelson, Andrew D Redd, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2021
Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020Adrienne E Shapiro, Rachel A Bender Ignacio, Bridget M Whitney, et al.
Annals of Internal Medicine|August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized TrialRoy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Plos Genetics|April 26, 2014
Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemicLaura A Cotton, Xiaomei T Kuang, Anh Q Le, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 1, 2022
Factors Associated With Severity of COVID-19 Disease in a Multicenter Cohort of People With HIV in the United States, March-December 2020Adrienne E Shapiro, Rachel A Bender Ignacio, Bridget M Whitney, et al.
AIDS and Behavior|October 28, 2024
Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time among People with HIV in the Current Treatment EraJimmy Ma, Joseph A C Delaney, Stephanie A Ruderman, et al.
Pageof 100